Trials / Recruiting
RecruitingNCT06529432
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
Efficacy, Safety and Pharmacokinetics of Bupivacaine Liposome Injection for Paravertebral Nerve Block in the Treatment of Postoperative Pain After Thoracoscopic Surgery: a Multicenter, Randomized, Double-blind, Dose-finding, Positive Control, Phase Ⅱ Clinical Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy, safety, and tolerability of bupivacaine liposomes for paravertebral nerve block in the treatment of thoracoscopic postoperative pain, and to evaluate the relevant human pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupivacaine Liposome Injection | Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose |
| DRUG | Bupivacaine Hydrochloride Injection | Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose |
Timeline
- Start date
- 2026-03-03
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2024-07-31
- Last updated
- 2026-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06529432. Inclusion in this directory is not an endorsement.